CytomX Therapeutics Inc. (NASDAQ:CTMX) Director Ix L.P. Canaan sold 86,270 shares of the business’s stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $11.16, for a total transaction of $962,773.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ix L.P. Canaan also recently made the following trade(s):

  • On Wednesday, November 9th, Ix L.P. Canaan sold 13,730 shares of CytomX Therapeutics stock. The stock was sold at an average price of $11.03, for a total transaction of $151,441.90.

Shares of CytomX Therapeutics Inc. (NASDAQ:CTMX) opened at 11.31 on Tuesday. The company’s 50 day moving average is $13.13 and its 200-day moving average is $11.73. CytomX Therapeutics Inc. has a 1-year low of $9.10 and a 1-year high of $24.68. The company’s market capitalization is $411.71 million.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Separately, Zacks Investment Research downgraded shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday.

A number of large investors have recently made changes to their positions in the company. BlackRock Advisors LLC increased its stake in shares of CytomX Therapeutics by 21,170.0% in the second quarter. BlackRock Advisors LLC now owns 542,384 shares of the company’s stock worth $5,541,000 after buying an additional 539,834 shares during the last quarter. Tekla Capital Management LLC increased its stake in shares of CytomX Therapeutics by 130.5% in the second quarter. Tekla Capital Management LLC now owns 756,090 shares of the company’s stock worth $7,723,000 after buying an additional 428,031 shares during the last quarter. BlackRock Fund Advisors increased its stake in shares of CytomX Therapeutics by 168.6% in the second quarter. BlackRock Fund Advisors now owns 527,248 shares of the company’s stock worth $5,386,000 after buying an additional 330,966 shares during the last quarter. Private Advisor Group LLC purchased a new stake in shares of CytomX Therapeutics during the second quarter worth about $2,232,000. Finally, State Street Corp increased its stake in shares of CytomX Therapeutics by 177.3% in the second quarter. State Street Corp now owns 254,501 shares of the company’s stock worth $2,599,000 after buying an additional 162,724 shares during the last quarter. Hedge funds and other institutional investors own 51.59% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.

5 Day Chart for NASDAQ:CTMX

Receive News & Stock Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related stocks with our FREE daily email newsletter.